CR9164A - Estabilizacion de esteres de glucocorticoides con acidos - Google Patents

Estabilizacion de esteres de glucocorticoides con acidos

Info

Publication number
CR9164A
CR9164A CR9164A CR9164A CR9164A CR 9164 A CR9164 A CR 9164A CR 9164 A CR9164 A CR 9164A CR 9164 A CR9164 A CR 9164A CR 9164 A CR9164 A CR 9164A
Authority
CR
Costa Rica
Prior art keywords
stabilization
acids
glucocorticoid
esters
glucocorticoid esters
Prior art date
Application number
CR9164A
Other languages
English (en)
Inventor
Dirk Mertin
Iris Heep
Georg Schulte
Ulrike Umgelder
Gert Daube
Ernst Bottcher
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35758903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9164(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE102005055385A external-priority patent/DE102005055385A1/de
Priority claimed from DE200510055386 external-priority patent/DE102005055386A1/de
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of CR9164A publication Critical patent/CR9164A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La invencion se refiere a preparados farmaceuticos no acuosos que contienen un ester de glucocorticoide y un acido, asi como a la estabilizacion de esteres de glucocorticoides en dichos preparados mediante acidos.
CR9164A 2004-12-09 2007-06-01 Estabilizacion de esteres de glucocorticoides con acidos CR9164A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004059220 2004-12-09
DE102005055385A DE102005055385A1 (de) 2004-12-09 2005-11-17 Arzneimittel zur hygienischen Applikation im Ohr
DE200510055386 DE102005055386A1 (de) 2005-11-17 2005-11-17 Stabilisierung von Glucocorticoidestern mit Säuren

Publications (1)

Publication Number Publication Date
CR9164A true CR9164A (es) 2008-03-03

Family

ID=35758903

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9164A CR9164A (es) 2004-12-09 2007-06-01 Estabilizacion de esteres de glucocorticoides con acidos

Country Status (13)

Country Link
US (2) US20090239835A1 (es)
EP (1) EP1827498A2 (es)
JP (1) JP5002462B2 (es)
KR (1) KR101217680B1 (es)
AU (1) AU2005313601B2 (es)
BR (1) BRPI0518853A2 (es)
CA (1) CA2591296A1 (es)
CR (1) CR9164A (es)
IL (1) IL183743A0 (es)
MX (1) MX2007006908A (es)
NO (1) NO20072998L (es)
NZ (1) NZ555641A (es)
WO (1) WO2006061155A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007055341A1 (de) * 2007-11-19 2009-05-20 Bayer Animal Health Gmbh Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren
GR20090100230A (el) 2009-04-14 2010-11-18 Casso Pharmaceuticals Ε.Π.Ε, Απο του στοματος εναιωρημα οξικης δεξαμεθανοζης-συνθεση καλυψης γευσης της δεξαμεθανοζης
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
MX2013013369A (es) * 2011-05-15 2014-10-17 Trimel Biopharma Srl Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino.
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
HK1223300A1 (zh) 2013-06-03 2017-07-28 Tolmar, Inc. 皮质类固醇组合物
EP3478269A4 (en) * 2016-06-29 2020-04-08 Otonomy, Inc. OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6032714B2 (ja) 1978-07-04 1985-07-30 新日本製鐵株式会社 表面処理鋼板
JPS5524131A (en) * 1978-08-09 1980-02-21 Nippon Redarii Kk Synthetic adrenal cortical hormone preparation ointment and its base
JPS6028923B2 (ja) 1979-05-28 1985-07-08 三井化学株式会社 エレクトレツト化捲縮繊維の製法
US4670444B1 (en) * 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
JPS6032714A (ja) * 1983-08-01 1985-02-19 Teijin Ltd 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物
DE3333719A1 (de) * 1983-09-17 1985-04-04 Bayer Ag Loesungen milchsaurer salze von piperazinylchinolon- und piperazinyl-azachinoloncarbonsaeuren
GB8420771D0 (en) * 1984-08-15 1984-09-19 Efamol Ltd Treatment of skin disorders
JPS61167614A (ja) * 1985-01-22 1986-07-29 Mitsubishi Yuka Yakuhin Kk ステロイド含有軟膏剤
DE3537761A1 (de) * 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
DE3713672A1 (de) * 1987-04-24 1988-11-17 Bayer Ag Verfahren zur herstellung von parenteral verabreichbaren chinoloncarbonsaeuren
US5444096A (en) * 1989-06-02 1995-08-22 Helene Curtis, Inc. Stable anhydrous topically-active composition and suspending agent therefor
DE19500784A1 (de) * 1995-01-13 1996-07-18 Bayer Ag Enrofloxacin-Injektions- oder Infusionslösungen
CA2176298C (en) * 1995-06-27 2009-01-27 Dennis D. Copeland A single high dose fluoroquinolone treatment
US5972920A (en) * 1998-02-12 1999-10-26 Dermalogix Partners, Inc. Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders
US6585997B2 (en) * 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds

Also Published As

Publication number Publication date
AU2005313601A1 (en) 2006-06-15
EP1827498A2 (de) 2007-09-05
IL183743A0 (en) 2007-09-20
BRPI0518853A2 (pt) 2008-12-09
AU2005313601B2 (en) 2012-05-24
NO20072998L (no) 2007-06-12
HK1117044A1 (en) 2009-01-09
KR20070086690A (ko) 2007-08-27
KR101217680B1 (ko) 2013-01-02
WO2006061155A2 (de) 2006-06-15
WO2006061155A3 (de) 2006-08-31
US20110301135A1 (en) 2011-12-08
JP2008522997A (ja) 2008-07-03
US20090239835A1 (en) 2009-09-24
MX2007006908A (es) 2007-08-03
NZ555641A (en) 2010-10-29
JP5002462B2 (ja) 2012-08-15
CA2591296A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
DE602008005035D1 (de) In ionischen flüssigkeiten erzeugte hydroxymethylfurfuralether und -ester
MY166613A (en) Glycerol levulinate ketals and their use
MX2009000520A (es) Metodos para producir combustibles y solventes.
MX350088B (es) Composicion farmaceutica estable y metodos de uso de la misma.
NZ622566A (en) Chromobacterium bioactive compositions and metabolites
NO20072998L (no) Stabilisering av glukokortikoidestere med syrer
WO2008123845A3 (en) Compositions comprising mono and di esters of biologically-based 1.3-propanediol
TW200712049A (en) Process for transesterification
ITMI20022627A1 (it) Uso di una miscela di esteri di acidi grassi come combustibile
GT201400105A (es) Composicion herbicida que contiene ciertos acidos piridina carboxilicos y el acido (2,4-diclorofenoxi) acetico
CR7478A (es) Composicion pesticida que comprende un ester lactato como inhibidor de crecimiento de cristal
UY29395A1 (es) Formulación de medicamentos conteniendo vardenafilo.
PE20011223A1 (es) Composicion farmaceutica que comprende pemetrexed y un antioxidante como monotioglicerol, l-cisteina y acido tioglicolico
GR20080100541A (el) Παρασιτοκτονος συνθεση
MX2007004884A (es) Generacion de plantas con contenido alterado de aceite.
ITMI20040347A1 (it) Nuovo farmaco di associazione
MX339727B (es) Composicion farmaceutica que comprende un compuesto de 11-desoxi-prostaglandina y metodo para estabilizar el compuesto.
AR076359A1 (es) Biocarburante constituido por una mezcla de esteres de acidos grasos de origen natural, y proceso de fabricacion de dicho biocarburante
MX2007006775A (es) Composiciones estables de fenofibrato con esteres de acido graso.
GR20080100543A (el) Παρασιτοκτονος συνθεση
TW200600583A (en) Method for kinetic resolution of α-substituted acids and esters thereof
PL2004149T3 (pl) Preparaty farmaceutyczne zawierające leflunomid
BRPI0418664A (pt) método para produzir um derivado de ácido (met) acrìlico
UA88663C2 (en) Stabilisation of glucocorticoid esters with acids
WO2004056967A3 (en) Generation of plants with altered oil content